Table 2.
Overall χ2 Test of Compliance for Zolpidem Prescriptions in Women Before and After the US Food and Drug Administration (FDA) Communication
| Time Point | In Compliance, n (%) | Odds Ratio (95% CI) | P Value |
| Post-FDA communication | 1,046 (15.5) | 1.49 (1.35–1.65) | < .0001 |
| Pre-FDA communication | 809 (10.9) | Reference |